Accéder au contenu
Merck

Complex relationship between ligand binding and dimerization in the epidermal growth factor receptor.

Cell reports (2014-12-03)
Nicholas J Bessman, Atrish Bagchi, Kathryn M Ferguson, Mark A Lemmon
RÉSUMÉ

The epidermal growth factor receptor (EGFR) plays pivotal roles in development and is mutated or overexpressed in several cancers. Despite recent advances, the complex allosteric regulation of EGFR remains incompletely understood. Through efforts to understand why the negative cooperativity observed for intact EGFR is lost in studies of its isolated extracellular region (ECR), we uncovered unexpected relationships between ligand binding and receptor dimerization. The two processes appear to compete. Surprisingly, dimerization does not enhance ligand binding (although ligand binding promotes dimerization). We further show that simply forcing EGFR ECRs into preformed dimers without ligand yields ill-defined, heterogeneous structures. Finally, we demonstrate that extracellular EGFR-activating mutations in glioblastoma enhance ligand-binding affinity without directly promoting EGFR dimerization, suggesting that these oncogenic mutations alter the allosteric linkage between dimerization and ligand binding. Our findings have important implications for understanding how EGFR and its relatives are activated by specific ligands and pathological mutations.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Epidermal Growth Factor Receptor human, lyophilized powder, ≥15,000 units/mg protein (Bradford)
Sigma-Aldrich
Epidermal Growth Factor Receptor human, buffered aqueous glycerol solution, 5,000-30,000 units/mg protein (Lowry)